3-(2-aminoimidazol-1-yl)propanoic Acid | 215229-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2-aminoimidazol-1-yl)propanoic Acid
• CAS: 215229-20-2
• 化学式: C₆H₉N₃O₂
• mdl: MFCD01318232
• 分子量: 155.15
• InChiKey: XUASGMPEHGZUOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  81.1
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE<br/>[FR] INHIBITEURS D'ALPHA-CETOAMIDES DE LA PROTEASE NS3 DU VIRUS DE L'HEPATITE C
  申请人：DU PONT PHARM CO

  公开号：WO2001040262A1

  公开（公告）日：2001-06-07

  The present invention relates to ketoamide and ketoester compounds of Formula (I): where W is -NH- or -O-, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及式(I)的酮酰胺和酮酯化合物：其中W为-NH-或-O-，或其立体异构体、立体异构体混合物或药学上可接受的盐形式，它们可用作HCV NS3蛋白酶的抑制剂，以及包含它们的制药组合物和诊断试剂盒，以及将它们用于治疗病毒感染或作为测定标准或试剂的方法。
• PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1196436A2

  公开（公告）日：2002-04-17
• ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1252178A1

  公开（公告）日：2002-10-30
• INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1261611A2

  公开（公告）日：2002-12-04
• [EN] PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE<br/>[FR] INHIBITEURS DE LA PROTEASE DU VIRUS DE L'HEPATITE C A BASE D'ACIDE BORONIQUE PEPTIDE
  申请人：DU PONT PHARM CO

  公开号：WO2001002424A2

  公开（公告）日：2001-01-11

  The present invention relates generally to novel α-aminoboronic acids and corresponding peptide analogs represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R?1, R2, R3, Y1, Y2¿, and A are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of hepatitis C viral infections. The compounds of the invention are inhibitors of hepatitis C viral protease.